Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-001525
Filing Date
2024-03-18
Accepted
2024-03-18 16:02:07
Documents
72
Period of Report
2024-01-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR JAN 2024 pharmacyte_i10q-013124.htm   iXBRL 10-Q 1059537
2 CERTIFICATION pharmacyte_ex3101.htm EX-31.1 8837
3 CERTIFICATION pharmacyte_ex3102.htm EX-31.2 8802
4 CERTIFICATION pharmacyte_ex3201.htm EX-32.1 4413
5 CERTIFICATION pharmacyte_ex3202.htm EX-32.2 4410
  Complete submission text file 0001683168-24-001525.txt   5738839

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE pmcb-20240131.xsd EX-101.SCH 46842
7 XBRL CALCULATION FILE pmcb-20240131_cal.xml EX-101.CAL 53215
8 XBRL DEFINITION FILE pmcb-20240131_def.xml EX-101.DEF 223951
9 XBRL LABEL FILE pmcb-20240131_lab.xml EX-101.LAB 359792
10 XBRL PRESENTATION FILE pmcb-20240131_pre.xml EX-101.PRE 336889
76 EXTRACTED XBRL INSTANCE DOCUMENT pharmacyte_i10q-013124_htm.xml XML 827154
Mailing Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653
Business Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653 (917) 595.2850
PharmaCyte Biotech, Inc. (Filer) CIK: 0001157075 (see all company filings)

EIN.: 621772151 | State of Incorp.: NV | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40699 | Film No.: 24758921
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)